Medical disclaimer: This article is for informational purposes, represents the views of its authors and does not replace professional medical advice. Always consult healthcare professionals for medical advice, diagnosis, or treatment.
Important context: Intismeran autogene is an investigational treatment. It is not currently approved for routine use, and the available Phase 3 information is a sponsor-reported top-line announcement rather than a complete published dataset. This article should not be used to start, stop, or change any treatment.
On 19 August 2026, Moderna and Merck announced positive top-line results from a large Phase 3 trial of a personalized mRNA treatment for people with high-risk melanoma that had been completely removed by surgery. The result is an important research milestone, but important questions remain until the complete data are presented and reviewed. [1]
INTerpath-001 is a randomized, blinded Phase 3 study in adults with completely resected stage IIB to IV cutaneous melanoma. The registered comparison is intismeran autogene plus pembrolizumab (Keytruda) versus a dose-matched placebo plus pembrolizumab. The companies report that 1,137 participants were enrolled. [1,2]
According to the sponsor announcement, the combination produced statistically significant and clinically meaningful improvements in both recurrence-free survival—the time before melanoma returned or a participant died—and distant metastasis-free survival—the time before melanoma spread to a distant part of the body or a participant died. The companies also reported that no new safety signals were observed at this analysis. [1]
However, the announcement did not include hazard ratios, absolute event rates, detailed adverse-event results, or overall survival results. This means we do not yet know the size of the Phase 3 benefit. The study is continuing to assess other outcomes, including overall survival, and the detailed findings are expected at a future international medical meeting. [1,2]
Intismeran autogene, previously known as V940 or mRNA-4157, is made individually for each patient. Researchers analyze a sample of the person’s tumor, identify mutations that may produce tumor-specific targets called neoantigens, and create synthetic mRNA encoding up to 34 of those targets. The aim is to help the immune system generate T-cell responses that recognize the patient’s cancer cells. [1]
The treatment is given with pembrolizumab, an anti-PD-1 immunotherapy. Although intismeran is often described as a “cancer vaccine,” it is a personalized treatment intended for people who have already had melanoma. It is not a preventive vaccine for the general public. [1,2]
Merck and Moderna describe this as the first positive Phase 3 result for an individualized neoantigen therapy and for an mRNA-based cancer therapy. If the complete results support the announcement and regulators approve the combination, it could provide a new treatment option after surgery for people at high risk of melanoma returning. [1]
The result builds on a smaller randomized Phase 2b study involving 157 participants with resected high-risk melanoma. At five years, intismeran plus pembrolizumab was associated with a 49% lower risk of recurrence or death and a 59% lower risk of distant metastasis or death compared with pembrolizumab alone. The five-year analysis was descriptive, and the study was supported by Moderna and Merck. These figures are encouraging, but they are from the earlier Phase 2b study and should not be assumed to be the final Phase 3 effect sizes. [3]
For now, this announcement does not change routine melanoma prevention, early detection, or currently approved treatment. Continue to protect your skin from ultraviolet radiation and become familiar with your skin. A new spot, or a change in the size, shape, or color of an existing spot, should be assessed by a doctor. [4]
People who have been diagnosed with melanoma should discuss appropriate treatment and clinical-trial options with their oncology team. Do not delay approved care or seek an unregulated “melanoma vaccine” based on this announcement.
Source review completed and article last reviewed: 20 August 2026.